Michael Mydra Joins Moximed as Senior VP of Reimbursement and Market Access

Moximed has enlisted Michael Mydra to join the company as senior vice president of Reimbursement and Market Access.

“Michael has demonstrated the ability to achieve coding, coverage, and payment for multiple medical technologies,” Moximed President/CEO Christopher Gleason said. “He is a tremendous addition to the Moximed team. The experience he has gained from establishing five Category I CPT codes will be instrumental as we expand access of the MISHA Knee System.”

Mydra held the same position at PainTEQ before joining Moximed. Prior to that, he held reimbursement and market access leadership roles at various medical technology companies, including Sanarus Medical, Vertos Medical, SI-BONE, Boston Scientific Corp., and Profound Medical.

“It is an honor to join the team at Moximed,” Mydra stated. “The clinical evidence supporting the MISHA Knee System is robust and will continue to grow. I am eager to help expand access to this disruptive technology as we look to transform the lives of millions of people affected by knee osteoarthritis.”

Moximed’s MISHA Knee System is designed to treat people suffering from medial knee osteoarthritis (OA) who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities and are ineligible for, or unwilling to undergo, joint replacement due to their age or absence of advanced OA.

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.¹

The MISHA Knee System is cleared by the U.S. Food and Drug Administration.

Moximed’s technology, the MISHA Knee System, resulted from more than a decade of clinical research and development and is the first implantable shock absorber for treating medial compartment knee OA. The company is based in Fremont, Calif.

Reference
¹ Morgan OJ, Hillstrom HJ, Ranawat A, Fragomen AT, Rozbruch SR, Hillstrom R. Effects of a Medial Knee Unloading Implant on Tibiofemoral Joint Mechanics During Walking. J Orthop Res. 2019;37(10):2149-2156. doi:10.1002/jor.24379.